Search results for "Liver function"

showing 10 items of 176 documents

Tauroursodeoxycholic acid for the treatment of chronic hepatitis: a multicentre dose-response study

1998

Ursodeoxycholic acid (UDCA) improves the biochemical expression of chronic liver disease. Tauroursodeoxycholic acid (TUDCA) was recently shown to have more favourable metabolic properties. We designed a multicenter, randomized, controlled study, aimed at assessing the efficacy of TUDCA for the treatment of chronic hepatitis. One hundred and fifty-five patients with chronic hepatitis were randomly assigned to receive TUDCA at the daily doses of 250, 500 and 1000 mg, or no treatment for 6 months. Aminotransferase and gamma-glutamyl transpeptidase (GGT) serum levels decreased with each dose of TUDCA compared with controls (P<0.001). The 1000 mg dose was followed by more marked improvement comp…

Hepatitismedicine.medical_specialtyChemotherapyHepatologybusiness.industrymedicine.medical_treatmentTauroursodeoxycholic acidChronic liver diseasemedicine.diseaseGastroenterologyUrsodeoxycholic acidchemistry.chemical_compoundLiver diseaseDose–response relationshipInfectious DiseasesEndocrinologychemistryInternal medicineMedicineLiver functionbusinessmedicine.drugHepatology Research
researchProduct

The New Era of Hepatitis C

2017

Hepatitis C virus (HCV) is the leading cause of end-stage liver disease in both Europe and the United States and is the most common reason for liver transplant. In the absence of antiviral therapy, recurrent infection is the norm with subsequent graft hepatitis and impaired survival. Whether it may be better to postpone therapy in patients in whom higher risk of failure and toxicity is coupled with lower chance of liver function improvement likely depends on several factors, including waiting time, center allocation policy, presence of hepatocellular carcinoma and local prevalence of anti-HCV-positive donors.

Hepatitismedicine.medical_specialtyCirrhosisHepatologybusiness.industryHepatitis C virusHepatitis C030230 surgerymedicine.diseasemedicine.disease_causeVirologyGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicineHepatocellular carcinomaToxicitymedicine030211 gastroenterology & hepatologyLiver functionbusinessClinics in Liver Disease
researchProduct

AB0438 Safety of tnf blockers in case of non-alcoholic fatty liver disease and cirrhosisa systematic review

2018

Background The management of inflammatory rheumatisms and psoriasis has largely evolved over the last 15 years with the emergence of biotherapies whose main adverse effect is the increased infection risk. The prevalence of metabolic syndrome is increasing and has been estimated at 30% in patients with rheumatoid arthritis with an excess of 45% compared to healthy subjects. One of the major complications of the metabolic syndrome is the Non Alcoholic Fatty Liver Disease (NAFLD), which prevalence is 25% in the global population, and 30% in a cohort of patients with rheumatoid arthritis. The main complication of NAFLD is the development of cirrhosis, known to increase infectious risk. Surprisi…

Hepatitismedicine.medical_specialtyCirrhosisbusiness.industryAutoimmune hepatitisHepatitis Bmedicine.diseaseGastroenterologyInfliximabEtanerceptInternal medicinemedicineAdalimumabLiver functionbusinessmedicine.drugRheumatoid arthritis – biological DMARDs
researchProduct

Autoimmune Lebererkrankungen: Diagnostik und Therapie

2004

Autoimmune Hepatitis (AIH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and overlap syndromes of these three disease entities are regarded as autoimmune liver diseases. These conditions are important differential diagnoses of elevated liver function tests as about 10 % of liver transplantations in Europe and North America are for these indications. The diagnosis is often difficult but can be facilitated by sequential measurement of relevant autoantibodies, exclusion of other liver disease, ultrasound, ERCP and liver histology. In AIH immunosuppressive therapy has been shown to prevent or stop the development of cirrhosis and improve the prognosis of the patients de…

Hepatitismedicine.medical_specialtyCirrhosismedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentGastroenterologyAutoimmune hepatitisLiver transplantationmedicine.diseaseGastroenterologydigestive system diseasesPrimary sclerosing cholangitisLiver diseasePrimary biliary cirrhosisInternal medicineImmunologyMedicinebusinessLiver function testsZeitschrift für Gastroenterologie
researchProduct

The new murine hepatic 3A cell line responds to stress stimuli by activating an efficient Unfolded Protein Response (UPR)

2012

In the present study we have investigated the properties of a novel cell line (3A cells) obtained from the liver of 14.5. days post coitum (dpc) wild-type mouse embryo. 3A cells morphology was characterized by fluorescent localization of F-actin and β-catenin. The expression of specific genes and proteins essential to liver function in these cells was comparable or even more efficient then in the differentiated hepatocytic cell line MMH-D6. 3A cells also showed the capability to excrete molecules in extracellular spaces resembling functional bile canaliculi, glycogen storage activity and the ability to control retinol-binding protein 4 secretion in response to retinol deprivation. Their re…

Hepatocytes; ER stress; RBP4BiologyToxicologyCellular modelCell LineMicechemistry.chemical_compoundStress PhysiologicalExtracellularAnimalsHepatocyteSecretionActinbeta CateninAnimalReverse Transcriptase Polymerase Chain ReactionRBP4Gene Expression ProfilingTunicamycinDays post coitumCellular model; ER stress; Hepatocytes; RBP4; Actins; Animals; Cell Line; Fluorescein; Gene Expression Profiling; Glycogen; Liver; Retinol-Binding Proteins Plasma; Reverse Transcriptase Polymerase Chain Reaction; Stress Physiological; Tunicamycin; Unfolded Protein Response; beta Catenin; Mice; ToxicologyGeneral MedicineTunicamycinMolecular biologyActinsLiverchemistryCell cultureUnfolded Protein ResponseUnfolded protein responseER streFluoresceinLiver functionCellular modelRetinol-Binding Proteins PlasmaGlycogenToxicology in Vitro
researchProduct

Equines as reservoirs of human fascioliasis: transmission capacity, epidemiology and pathogenicity inFasciola hepatica-infected mules

2020

AbstractFascioliasis is a zoonotic disease caused by liver flukes transmitted by freshwater lymnaeid snails. Donkey and horse reservoir roles have been highlighted in human endemic areas. Liver fluke infection in mules has received very limited research. Their role in disease transmission, epidemiological importance andFasciola hepaticapathogenicity are studied for the first time. Prevalence was 39.5% in 81 mules from Aconcagua, and 24.4% in 127 from Uspallata, in high-altitude areas of Mendoza province, Argentina. A mean amount of 101,242 eggs/mule/day is estimated. Lymnaeids from Uspallata proved to belong to ribosomal DNA internal transcribed spacer (ITS) markers ITS-1 and ITS-2 combined…

InfectivityVeterinary medicinebiology040301 veterinary sciences030231 tropical medicine04 agricultural and veterinary sciencesGeneral MedicineSnailLiver flukebiology.organism_classification0403 veterinary science03 medical and health sciences0302 clinical medicineHepaticabiology.animalparasitic diseasesFasciola hepaticaAnimal Science and ZoologyParasitologyDonkeyLiver functionGalba truncatulaJournal of Helminthology
researchProduct

Voluntary distance running prevents TNF-mediated liver injury in mice through alterations of the intrahepatic immune milieu

2017

AbstractPhysical activity confers a broad spectrum of health benefits. Beyond the obvious role in metabolically driven diseases, the role of physical activity in acute liver injury is poorly explored. To study the role of physical activity in acute liver injury, a novel model of voluntary distance running in mice was developed and mice were subjected to acute liver injury induced by N-galactosamine (GalN) and lipopolysaccharide (LPS). Analyses included histological stains, immunoblotting, qRT-PCR and FACS analysis. Voluntary distance running increased to an average of 10.3 km/day after a learning curve. Running lead to a decrease in the absolute numbers of intrahepatic CD4+ T and B lymphocy…

Lifestyle modification0301 basic medicineLipopolysaccharidesMaleCancer ResearchChemokineApoptosisGalactosamineLiver Function TestsAlarminsLiver injurybiologymedicine.diagnostic_testChemotaxisNF-kappa Bmedicine.anatomical_structureLiverReceptors Pattern RecognitionModels AnimalCytokinesTumor necrosis factor alphaOriginal Articlemedicine.symptomChemokinesInflammation Mediatorsmedicine.medical_specialtyImmunologyInflammationCCL2Proinflammatory cytokine03 medical and health sciencesCellular and Molecular NeuroscienceInternal medicinePhysical Conditioning AnimalmedicineAnimalsLiver diseasesInflammationbusiness.industryTumor Necrosis Factor-alphaMonocyteBody WeightJNK Mitogen-Activated Protein KinasesCell BiologyLiver Failure Acutemedicine.diseaseEnzyme ActivationMice Inbred C57BL030104 developmental biologyEndocrinologyImmunologybiology.proteinLiver function testsbusinessCell Death & Disease
researchProduct

Circulating levels of 3-hydroxymyristate, a direct quantification of endotoxaemia in noninfected cirrhotic patients

2019

IF 4.5; International audience; Background & AimsThe quantification of lipopolysaccharide (LPS) in biological fluids is challenging. We aimed to measure plasma LPS concentration using a new method of direct quantification of 3‐hydroxymyristate (3‐HM), a lipid component of LPS, and to evaluate correlations between 3‐HM and markers of liver function, endothelial activation, portal hypertension and enterocyte damage.MethodsPlasma from 90 noninfected cirrhotic patients (30 Child‐Pugh [CP]‐A, 30 CP‐B, 30 CP‐C) was prospectively collected. The concentration of 3‐HM was determined by high‐performance liquid chromatography coupled with mass spectrometry.Results3‐HM levels were higher in CP‐C patien…

LipopolysaccharidesLiver CirrhosisMalemedicine.medical_specialtyCirrhosisLipopolysaccharidePilot ProjectsSeverity of Illness IndexGastroenterologyEndothelial activationendotoxaemia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk Factors3-HydroxymyristateInternal medicineHumansMedicinebacterial translocationHepatic encephalopathyChromatography High Pressure LiquidAgedHepatologybusiness.industrycirrhosislipopolysaccharideportal hypertensionMiddle Agedmedicine.diseaseEndotoxemia3. Good healthLogistic ModelschemistryHepatic Encephalopathy030220 oncology & carcinogenesisMultivariate AnalysisPortal hypertension[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemale030211 gastroenterology & hepatologyLiver function3-hydroxymyristatebusinessAcute Alcoholic HepatitisMyristic AcidsBiomarkersBlood Chemical Analysis
researchProduct

Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation

2019

Background & Aims Alpha-1 antitrypsin deficiency (AATD) is among the most common genetic disorders. Severe AATD is caused by a homozygous mutation in the SERPINA1 gene that encodes the Glu342Lys substitution (called the Pi*Z mutation, Pi*ZZ genotype). Pi*ZZ carriers may develop lung and liver diseases. Mutation-associated lung disorders have been well studied, but less is known about the effects in liver. We assessed the liver disease burden and associated features in adults with this form of AATD. Methods We collected data from 554 Pi*ZZ adults (403 in an exploratory cohort, 151 in a confirmatory cohort), in 9 European countries, with AATD who were homozygous for the Pi*Z mutation, and 234…

Liver CirrhosisMale0301 basic medicineALTLiver diseasechemistry.chemical_compound0302 clinical medicineLiver Function TestsRisk FactorsGenotypeRare Liver DiseaseAlpha 1-antitrypsin deficiencyHomozygoteAge FactorsGastroenterologyMiddle AgedEuropeEditorial CommentaryPhenotypemedicine.anatomical_structureLiverElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologyTEAdultmedicine.medical_specialty610Mice Transgenic03 medical and health sciencesSex Factorsalpha 1-Antitrypsin DeficiencyInternal medicinemedicinePiAnimalsHumansGenetic Predisposition to DiseaseASTAgedLungHepatologyTriglyceridebusiness.industryLipid Metabolismmedicine.diseaseFatty Liver030104 developmental biologyEndocrinologychemistryCase-Control Studiesalpha 1-AntitrypsinMutationSteatosisTransient elastographybusinessGastroenterology
researchProduct

Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma

2017

Background &amp; Aims Assessment of long-term outcome is required in hepatitis C virus (HCV)-infected patients with cirrhosis, who have been successfully treated for Barcelona Clinic Liver Cancer (BCLC) stage A hepatocellular carcinoma (HCC). However, problems arise due to the lack of models accounting for early changes during follow-up. The aim of this study was to estimate the impact of early events (HCC recurrence or hepatic decompensation within 12Â months of complete radiological response) on 5-year overall survival (OS) in a large cohort of patients with HCV and cirrhosis, successfully treated HCC. Methods A total of 328 consecutive Caucasian patients with HCV-related cirrhosis and BC…

Liver CirrhosisMaleHepatocellular Carcinoma Liver Cirrhosis hepatitis C virus Survival direct-acting antiviral agentsSurvival rateCirrhosisAntiviral agentGastroenterologyLiver cirrhosi0302 clinical medicineRecurrenceHepatic decompensation; Hepatitis C Virus (HCV); Hepatocellular carcinoma (HCC); Prognosis; Recurrences; Sustained virological response (SVR); overall survival (OS)Overall survivalLiver NeoplasmsHepatitis Coverall survival (OS)Middle AgedPrognosisHepatitis CSustained virological responseLocal030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleAntiviral agents; Carcinoma hepatocellular; Hepatic decompensation; Hepatitis C; Hepatocellular carcinoma (HCC); Liver cirrhosis; Overall survival; Prognosis; Recurrences; Survival rate; Sustained virological response; Aged; Carcinoma Hepatocellular; Female; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Proportional Hazards ModelsLiver cancerHepatic decompensationmedicine.medical_specialtyCarcinoma HepatocellularPrognosiSettore MED/12 - GASTROENTEROLOGIA03 medical and health scienceshepatocellularInternal medicinemedicineEarly Hepatocellular CarcinomaHumansRecurrencesHepatocellular carcinoma (HCC)Survival rateAntiviral agents; Carcinoma hepatocellular; Hepatic decompensation; Hepatitis C; Hepatocellular carcinoma (HCC); Liver cirrhosis; Overall survival; Prognosis; Recurrences; Survival rate; Sustained virological response; HepatologyAgedProportional Hazards ModelsHepatologybusiness.industryHepatitis C Virus (HCV)CarcinomaHepatocellularHepatologymedicine.diseasedigestive system diseasesNeoplasm RecurrenceAntiviral agentsLiver cirrhosisLiver functionNeoplasm Recurrence LocalbusinessSustained virological response (SVR)
researchProduct